Equity Details
Price & Market Data
Price: $0.36
Daily Change: +$0.0516 / 14.33%
Daily Range: $0.301 - $0.367
Market Cap: $2,286,901
Daily Volume: 293,321
Performance Metrics
1 Week: -17.03%
1 Month: -3.58%
3 Months: -66.38%
6 Months: -88.75%
1 Year: -93.48%
YTD: -65.01%
About HCW Biologics Inc. (HCWB)
Dive into the latest financial snapshot of HCW Biologics Inc. (HCWB). With a current trading price of 0.36, the stock has experienced a daily shift of +$0.0516 / 14.33%. The company's market capitalization stands impressively at 2,286,901. Track its year-to-date performance, which is at -65.01%, alongside its weekly, monthly, and yearly trends.
Company Details
Employees: 35
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, a clinical-stage bifunctional molecule, which has completed Phase 1 to treat chemotherapy-refractory solid tumor cancers and Phase 1b/2 to treat pancreatic cancer; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in phase 1 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201 and HCW9206, novel immunotherapeutic for memory-like natural killer cells, cancer, and pathogens; HCW11-006, an immune cell stimulator; HCW11-002 and HCW11-0027, which are immune checkpoint inhibitors to treat oncology and other senescence-associated indications; and HCW11-018, a fusions and immune cell engagers to treat cancer. The company has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecules. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.